ZURICH (Reuters) - Pharmaceuticals giant Novartis is pinning its hopes on a 43-year-old Harvard cancer research star to help fill gaps in its immuno-oncology arsenal after "missing the boat" on some promising therapies.
http://ift.tt/xePdMM
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire